CoChat
Sign Up
Cited by 482

The diverse functionality of NQO1 and its roles in redox control

Ross, David, Siegel, David·2021·Redox Biology
DOI 10.1016/j.redox.2021.101950PMC PMC8027776
Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.redox.2021.101950

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several CR-associated genes, including GPX3, HMGN2, NQO1 and ODC1 (encoding a rate-limiting enzyme of polyamine biosynthesis), possess or promote antioxidant activities.

    “Several CR-associated genes, including GPX3, HMGN2, NQO1 and ODC1 (encoding a rate-limiting enzyme of polyamine biosynthesis), possess or promote antioxidant activities61–66 (Fig. 5c–f and Supplementary Fig. 43a–d).”

    From Single-cell multiregion dissection of Alzheimer’s disease (2024) · cites this paper as [64]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 260

  1. [2]Ernster L. Diaphorase activities in liver cytoplasmic fractions Fed. Proc. 17 1958 216
  2. [4]Ernster L. Danielson L. Ljunggren M. DT diaphorase. I. Purification from the soluble fraction of rat-liver cytoplasm, and properties Biochim. Biophys. Acta 58 1962 171 188 13890666
  3. [6]Maerki F. Martius C. [Vitamin K reductase, preparation and properties] Biochem. Z. 333 1960 111 135 13765127
  4. [7]Maerki F. Martius C. [Vitamin K reductase, from cattle and ratliver] Biochem. Z. 334 1961 293 303 13765126
  5. [8]Ernster L. DT-Diaphorase: a historical review Chem. Scripta 27A 1987 1 13
  6. [9]Conover T.E. Ernster L. DT-Diaphorase II. Relation to respiratory chain of intact mitochondria Biochim. Biophys. Acta 58 1962 189 200 13880912
  7. [11]Preusch P.C. Smalley D.M. Vitamin K1 2,3-epoxide and quinone reduction: mechanism and inhibition Free Radic. Res. Commun. 8 1990 401 415 2113031
  8. [12]Gong X. Gutala R. Jaiswal A.K. Quinone oxidoreductases and vitamin K metabolism Vitam. Horm. 78 2008 85 101 18374191
  9. [13]Ingram B.O. Turbyfill J.L. Bledsoe P.J. Jaiswal A.K. Stafford D.W. Assessment of the contribution of NAD(P)H-dependent quinone oxidoreductase 1 (NQO1) to the reduction of vitamin K in wild-type and NQO1-deficient mice Biochem. J. 456 2013 47 54 24015818
  10. [14]Huggins C. Fukunishi R. Induced protection of adrenal cortex against 7,12- dimethylbenz(a)anthracene. Influence of ethionine. Induction of menadione reductase. Incorporation of thymidine-H3 J. Exp. Med. 119 1964 923 942 14179666 PMC2137757
  11. [15]Benson A.M. Hunkeler M.J. Talalay P. Increase of NAD(P)H:quinone reductase by dietary antioxidants. Possible role in protection against carcinogenesis and toxicity Proc. Natl. Acad. Sci. U.S.A. 77 1980 5216 5220 6933553 PMC350028
  12. [16]Talalay P. Benson A.M. Elevation of quinone reductase activity by anticarcinogenic antioxidants Adv. Enzym. Regul. 20 1981 287 300 6180607
  13. [17]Huggins C. Ford E. Fukunishi R. Jensen E.V. Aromatic-induced prevention of fetal toxicity of 7,12-dimethylbenz(Alpha)Anthracene J. Exp. Med. 119 1964 943 954 14176292 PMC2137759
  14. [18]Huggins C.B. Ford E. Jensen E.V. Carcinogenic aromatic hydrocarbons: special vulnerability of rats Science 147 1965 1153 1154 14242035
  15. [19]Williams-Ashman H.G. Huggins C. Oxydation of reduced pyridine nucleotides in mammary gland and adipose tissue following treatment with polynuclear hydrocarbons Med Exp Int J Exp Med 4 1961 223 226 14007238
  16. [20]Ross D. Kepa J.K. Winski S.L. Beall H.D. Anwar A. Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms Chem. Biol. Interact. 129 2000 77 97 11154736
  17. [21]Siegel D. Yan C. Ross D. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones Biochem. Pharmacol. 83 2012 1033 1040 22209713 PMC3482497
  18. [22]Siegel D. Gibson N.W. Preusch P.C. Ross D. Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C- induced DNA damage and cytotoxicity in human colon carcinoma cells Canc. Res. 50 1990 7483 7489 1701346
  19. [23]Siegel D. Gibson N.W. Preusch P.C. Ross D. Metabolism of diaziquone by NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase): role in diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells Canc. Res. 50 1990 7293 7300 2121335
  20. [24]Guo W. Reigan P. Siegel D. Zirrolli J. Gustafson D. Ross D. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition Canc. Res. 65 2005 10006 10015 16267026
  21. [25]Chesis P.L. Levin D.E. Smith M.T. Ernster L. Ames B.N. Mutagenicity of quinones: pathways of metabolic activation and detoxification Proc. Natl. Acad. Sci. U.S.A. 81 1984 1696 1700 6584903 PMC344985
  22. [26]Lind C. Hochstein P. Ernster L. DT-Diaphorase as a quinone reductase: a cellular control device against semiquinone and superoxide radical formation Arch. Biochem. Biophys. 216 1982 178 185 6285828
  23. [27]Thor H. Smith M.T. Hartzell P. Bellomo G. Jewell S.A. Orrenius S. The metabolism of menadione (2-methyl-1,4-naphthoquinone) by isolated hepatocytes. A study of the implication of oxidative stress in intact cells J. Biol. Chem. 257 1982 12419 12425 6181068
  24. [28]Prochaska H.J. Talalay P. Sies H. Direct protective effect of NAD(P)H:quinone reductaseagainst menadione-induced chemiluminescence of postmitochondrial fractions of mouse liver J. Biol. Chem. 262 1987 1931 1934 2434474
  25. [29]Wefers H. Sies H. Hepatic low-level chemiluminescence during redox cycling of menadione and the menadione-glutathione conjugate: relation to glutathione and NAD(P)H:quinone reductase (DT-diaphorase) activity Arch. Biochem. Biophys. 224 1983 568 578 6191666
  26. [30]Atallah A.S. Landolph J.R. Ernster L. Hochstein P. DT-diaphorase activity and the cytotoxicity of quinones in C3H/10T1/2 mouse embryo cells Biochem. Pharmacol. 37 1988 2451 2459 2455523
  27. [31]Iyanagi T. Yamazaki I. Difference in the mechanism of quinone reduction by the NADH dehydrogenase and the NAD(P)H dehydrogenase (DT-diaphorase) Biochim. Biophys. Acta 216 1970 282 294 4396182
  28. [32]Tedeschi G. Chen S. Massey V. DT-diaphorase. Redox potential, steady-state, and rapid reaction studies J. Biol. Chem. 270 1995 1198 1204 7836380
  29. [33]Bianchet M.A. Faig M. Amzel L.M. Structure and mechanism of NAD[P]H:quinone acceptor oxidoreductases (NQO) Methods Enzymol. 382 2004 144 174 15047101
  30. [35]Foster C.E. Bianchet M.A. Talalay P. Faig M. Amzel L.M. Structures of mammalian cytosolic quinone reductases Free Radic. Biol. Med. 29 2000 241 245 11035252
  31. [36]Faig M. Bianchet M.A. Talalay P. Chen S. Winski S. Ross D. Mario A.L. Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: species comparison and structural changes with substrate binding and release Proc. Natl. Acad. Sci. U. S. A 97 2000 3177 3182 10706635 PMC16212
  32. [37]Thomas D.J. Sadler A. Subrahmanyam V.V. Siegel D. Reasor M.J. Wierda D. Ross D. Bone marrow stromal cell bioactivation and detoxification of the benzene metabolite hydroquinone: comparison of macrophages and fibroblastoid cells Mol. Pharmacol. 37 1990 255 262 2154673
  33. [38]Smart R.C. Zannoni V.G. DT-Diaphorase and peroxidase influence the covalent binding of the metabolites of phenol, the major metabolite of benzene Mol. Pharmacol. 26 1984 105 111 6749127
  34. [39]Ross D. Siegel D. Schattenberg D.G. Sun X.M.M. Moran J.L. Cell-specific activation and detoxification of benzene metabolites in mouse and human bone marrow: identification of target cells and a potential role for modulation of apoptosis in benzene toxicity. Environ. Health Perspect 104 Supplement 6 1996 1177 1182 PMC1469724 9118890
  35. [40]Moran J.L. Siegel D. Ross D. A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H:quinone oxidoreductase 1 (NQO1) to benzene toxicity Proc. Natl. Acad. Sci. U. S. A 96 1999 8150 8155 10393963 PMC22203
  36. [41]Rothman N. Smith M.T. Hayes R.B. Traver R.D. Hoener B. Campleman S. Li G.L. Dosemeci M. Linet M. Zhang L. Xi L. Wacholder S. Lu W. Meyer K.B. Titenko-Holland N. Stewart J.T. Yin S. Ross D. Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C-->T mutation and rapid fractional excretion of chlorzoxazone Canc. Res. 57 1997 2839 2842 9230185
  37. [42]Wan J. Shi J. Hui L. Wu D. Jin X. Zhao N. Huang W. Xia Z. Hu G. Association of genetic polymorphisms in CYP2E1, MPO, NQO1, GSTM1, and GSTT1 genes with benzene poisoning Environ. Health Perspect. 110 2002 1213 1218 12460800 PMC1241108
  38. [43]Chen Y. Li G. Yin S. Xu J. Ji Z. Xiu X. Liu L. Ma D. Genetic polymorphisms involved in toxicant-metabolizing enzymes and the risk of chronic benzene poisoning in Chinese occupationally exposed populations Xenobiotica 37 2007 103 112 17178637
  39. [44]Iarc Benzene. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans vol. 120 2020 France IARC, Lyon
  40. [45]Cadenas E. Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism Biochem. Pharmacol. 49 1995 127 140 7530954
  41. [46]Ross D. Siegel D. Beall H. Prakash A.S. Mulcahy R.T. Gibson N.W. DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C Canc. Metastasis Rev. 12 1993 83 101 8375023
  42. [47]Ross D. Thor H. Threadgill M.D. Sandy M.S. Smith M.T. Moldeus P. Orrenius S. The role of oxidative processes in the cytotoxicity of substituted 1,4-naphthoquinones in isolated hepatocytes Arch. Biochem. Biophys. 248 1986 460 466 3017211
  43. [48]Buffinton G. Ollinger K. Brunmark A. Cadenas E. DT-Diaphorase catalyzed reduction of 1,4-naphthoquinone derivatives and glutathionyl-quinone conjugates. Effects of substituents on autoxidation rates Biochem. J. 256 1989 561 571 PMC1135615 2494985
  44. [49]Munday R. Smith B.L. Munday C.M. Effect of butylated hydroxyanisole on the toxicity of 2-hydroxy-1,4- naphthoquinone to rats Chem. Biol. Interact. 117 1999 241 256 10190578
  45. [50]Munday R. Activation and detoxification of naphthoquinones by NAD(P)H: quinone oxidoreductase Methods Enzymol. 382 2004 364 380 15047112
  46. [51]Munday R. Smith B.L. Munday C.M. Effect of inducers of DT-diaphorase on the haemolytic activity and nephrotoxicity of 2-amino-1,4-naphthoquinone in rats Chem. Biol. Interact. 155 2005 140 147 16045903
  47. [52]Powis G. Metabolism and reactions of quinoid anticancer agents Pharmacol. Ther. 35 1987 57 162 3321102
  48. [53]Ross D. Beall H.D. Siegel D. Traver R.D. Gustafson D.L. Enzymology of bioreductive drug activation Br. J. Canc. 74 Suppl. XXVII 1996 S1 S8 PMC2150032 8763836
  49. [54]Beall H.D. Mulcahy R.T. Siegel D. Traver R.D. Gibson N.W. Ross D. Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases Canc. Res. 54 1994 3196 3201 8205540
  50. [55]Bailey S.M. Lewis A.D. Knox R.J. Patterson L.H. Fisher G.R. Workman P. Reduction of the indoloquinone anticancer drug EO9 by purified DT-diaphorase: a detailed kinetic study and analysis of metabolites Biochem. Pharmacol. 56 1998 613 621 9783730
  51. [56]Choudry G.A. Stewart P.A. Double J.A. Krul M.R. Naylor B. Flannigan G.M. Shah T.K. Brown J.E. Phillips R.M. A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9 Br. J. Canc. 85 2001 1137 1146 PMC2375160 11710826
  52. [57]Dehn D.L. Winski S.L. Ross D. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H: quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1 Clin. Canc. Res. 10 2004 3147 3155 15131056
  53. [58]Dehn D.L. Inayat-Hussain S.H. Ross D. RH1 induces cellular damage in an NAD(P)H: quinone oxidoreductase 1-dependent manner: relationship between DNA cross-linking, cell cycle perturbations, and apoptosis J. Pharmacol. Exp. Therapeut. 313 2005 771 779 15665137
  54. [60]Bair J.S. Palchaudhuri R. Hergenrother P.J. Chemistry and biology of deoxynyboquinone, a potent inducer of cancer cell death J. Am. Chem. Soc. 132 2010 5469 5478 20345134
  55. [61]Siegel D. Ross D. Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues Free Radic. Biol. Med. 29 2000 246 253 11035253
  56. [62]Awadallah N.S. Dehn D. Shah R.J. Russell Nash S. Chen Y.K. Ross D. Bentz J.S. Shroyer K.R. NQO1 expression in pancreatic cancer and its potential use as a biomarker Appl. Immunohistochem. Mol. Morphol. 16 2008 24 31 18091324
  57. [63]Volpato M. Abou-Zeid N. Tanner R.W. Glassbrook L.T. Taylor J. Stratford I. Loadman P.M. Jaffar M. Phillips R.M. Chemical synthesis and biological evaluation of a NAD(P)H:quinone oxidoreductase-1 targeted tripartite quinone drug delivery system Mol. Canc. Therapeut. 6 2007 3122 3130 18089707
  58. [64]Huang B. Desai A. Tang S. Thomas T.P. Baker J.R. Jr. The synthesis of a c(RGDyK) targeted SN38 prodrug with an indolequinone structure for bioreductive drug release Org. Lett. 12 2010 1384 1387 20192275 PMC2851157
  59. [65]Sharma K. Iyer A. Sengupta K. Chakrapani H. INDQ/NO, a bioreductively activated nitric oxide prodrug Org. Lett. 15 2013 2636 2639 23659457
  60. [66]Liu P. Xu J. Yan D. Zhang P. Zeng F. Li B. Wu S. A DT-diaphorase responsive theranostic prodrug for diagnosis, drug release monitoring and therapy Chem. Commun. 51 2015 9567 9570 25971544
  61. [67]Shin W.S. Han J. Verwilst P. Kumar R. Kim J.H. Kim J.S. Cancer targeted enzymatic theranostic prodrug: precise diagnosis and chemotherapy Bioconjugate Chem. 27 2016 1419 1426 27135737
  62. [68]Li B. Liu P. Yan D. Zeng F. Wu S. A self-immolative and DT-diaphorase-activatable prodrug for drug-release tracking and therapy J. Mater. Chem. B 5 2017 2635 2643 32264042
  63. [69]Xu S. Yao H. Pei L. Hu M. Li D. Qiu Y. Wang G. Wu L. Yao H. Zhu Z. Xu J. Design, synthesis, and biological evaluation of NAD(P)H: quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation Eur. J. Med. Chem. 132 2017 310 321 28395199
  64. [70]Zhang X. Li X. Li Z. Wu X. Wu Y. You Q. Zhang X. An NAD(P)H: quinone oxidoreductase 1 responsive and self-immolative prodrug of 5-fluorouracil for safe and effective cancer therapy Org. Lett. 20 2018 3635 3638 29847952
  65. [71]Huang S.T. Peng Y.X. Wang K.L. Synthesis of a new long-wavelength latent fluorimetric indicator for analytes determination in the DT-Diaphorase coupling dehydrogenase assay system Biosens. Bioelectron. 23 2008 1793 1798 18403194
  66. [72]Hettiarachchi S.U. Prasai B. McCarley R.L. Detection and cellular imaging of human cancer enzyme using a turn-on, wavelength-shiftable, self-immolative profluorophore J. Am. Chem. Soc. 136 2014 7575 7578 24813575 PMC4046754
  67. [73]Prasai B. Silvers W.C. McCarley R.L. Oxidoreductase-facilitated visualization and detection of human cancer cells Anal. Chem. 87 2015 6411 6418 26005900
  68. [74]Shen Z. Prasai B. Nakamura Y. Kobayashi H. Jackson M.S. McCarley R.L. A near-infrared, wavelength-shiftable, turn-on fluorescent probe for the detection and imaging of cancer tumor cells ACS Chem. Biol. 12 2017 1121 1132 28240865 PMC7900918
  69. [75]Ong W. Yang Y. Cruciano A.C. McCarley R.L. Redox-triggered contents release from liposomes J. Am. Chem. Soc. 130 2008 14739 14744 18841890 PMC2590935
  70. [76]Gayam S.R. Venkatesan P. Sung Y.M. Sung S.Y. Hu S.H. Hsu H.Y. Wu S.P. An NAD(P)H:quinone oxidoreductase 1 (NQO1) enzyme responsive nanocarrier based on mesoporous silica nanoparticles for tumor targeted drug delivery in vitro and in vivo Nanoscale 8 2016 12307 12317 27271875
  71. [77]Park J. Jo S. Lee Y.M. Saravanakumar G. Lee J. Park D. Kim W.J. Enzyme-triggered disassembly of polymeric micelles by controlled depolymerization via cascade cyclization for anticancer drug delivery ACS Appl. Mater. Interfaces 13 7 2021 8060 8070 33576220
  72. [78]Li H. Li Q. Hou W. Zhang J. Yu C. Zeng D. Liu G. Li F. Enzyme-catalytic self-triggered release of drugs from a nanosystem for efficient delivery to nuclei of tumor cells ACS Appl. Mater. Interfaces 11 2019 43581 43587 31664812
  73. [79]Lind C. Cadenas E. Hochstein P. Ernster L. DT-Diaphorase. Purification properties and function Methods Enzymol. 186 1990 287 301 2233301
  74. [80]Beyer R.E. Segura-Aguilar J. Di Bernardo S. Cavazzoni M. Fato R. Fiorentini D. Galli M. Setti M. Landi L. Lenaz G. The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems Proc. Natl. Acad. Sci. U.S.A. 93 1996 2528 2532 8637908 PMC39831
  75. [81]Landi L. Fiorentini D. Galli M.C. Segura-Aguilar J. Beyer R.E. DT-diaphorase maintains the reduced state of ubiquinones in lipid vesicles thereby promoting their antioxidant function Free Radic. Biol. Med. 22 1997 329 335 8958158
  76. [82]Liebler D.C. The role of metabolism in the antioxidant function of vitamin E Crit. Rev. Toxicol. 23 1993 147 169 8329114
  77. [83]Siegel D. Bolton E.M. Burr J.A. Liebler D.C. Ross D. The reduction of alpha-tocopherolquinone by human NAD(P)H: quinone oxidoreductase: the role of alpha-tocopherol hydroquinone as a cellular antioxidant Mol. Pharmacol. 52 1997 300 305 9271353
  78. [84]Cadenas E. Hochstein P. Ernster L. Pro-and antioxidant functions of quinones and quinone reductases in mammalian cells Adv. Enzymol. Relat. Area Mol. Biol. 65 1992 97 146 1570770
  79. [85]Moore A.N. Ingold K.U. alpha-Tocopheryl quinone is converted into vitamin E in man Free Radic. Biol. Med. 22 1997 931 934 9119264
  80. [86]Cavalieri E. Chakravarti D. Guttenplan J. Hart E. Ingle J. Jankowiak R. Muti P. Rogan E. Russo J. Santen R. Sutter T. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention Biochim. Biophys. Acta 1766 2006 63 78 16675129
  81. [87]Cavalieri E. Frenkel K. Liehr J.G. Rogan E. Roy D. Estrogens as endogenous genotoxic agents–DNA adducts and mutations J. Natl. Cancer Inst. Monogr. 2000 75 93 10963621
  82. [88]Gaikwad N.W. Rogan E.G. Cavalieri E.L. Evidence from ESI-MS for NQO1-catalyzed reduction of estrogen ortho-quinones Free Radic. Biol. Med. 43 2007 1289 1298 17893042 PMC2064005
  83. [89]Chandrasena R.E. Edirisinghe P.D. Bolton J.L. Thatcher G.R. Problematic detoxification of estrogen quinones by NAD(P)H-dependent quinone oxidoreductase and glutathione-S-transferase Chem. Res. Toxicol. 21 2008 1324 1329 18588320
  84. [90]Shen L. Pisha E. Huang Z.W. Pezzuto J.M. Krol E. Alam Z. Breemen Van R. B. Bolton J.L. Bioreductive activation of catechol estrogen-ortho-quinones: aromatization of the B ring in 4-hydroxyequilenin markedly alters quinoid formation and reactivity Carcinogenesis 18 1997 1093 1101 9163701
  85. [91]Nutter L.M. Zhou B. Sierra E.E. Wu Y.Y. Rummel M.M. Gutierrez P. Abul-Hajj Y. Cellular biochemical determinants modulating the metabolism of estrone 3,4-quinone Chem. Res. Toxicol. 7 1994 609 613 7841338
  86. [92]Gaikwad N.W. Yang L. Rogan E.G. Cavalieri E.L. Evidence for NQO2-mediated reduction of the carcinogenic estrogen ortho-quinones Free Radic. Biol. Med. 46 2009 253 262 18996184 PMC2746554
  87. [93]Singh S. Zahid M. Saeed M. Gaikwad N.W. Meza J.L. Cavalieri E.L. Rogan E.G. Chakravarti D. NAD(P)H:quinone oxidoreductase 1 Arg139Trp and Pro187Ser polymorphisms imbalance estrogen metabolism towards DNA adduct formation in human mammary epithelial cells J. Steroid Biochem. Mol. Biol. 117 2009 56 66 19628038 PMC4425209
  88. [94]Yang L. Zahid M. Liao Y. Rogan E.G. Cavalieri E.L. Davidson N.E. Yager J.D. Visvanathan K. Groopman J.D. Kensler T.W. Reduced formation of depurinating estrogen-DNA adducts by sulforaphane or KEAP1 disruption in human mammary epithelial MCF-10A cells Carcinogenesis 34 2013 2587 2592 23843041 PMC3888356
  89. [95]Montano M.M. Bianco N.R. Deng H. Wittmann B.M. Chaplin L.C. Katzenellenbogen B.S. Estrogen receptor regulation of quinone reductase in breast cancer: implications for estrogen-induced breast tumor growth and therapeutic uses of tamoxifen Front. Biosci. 10 2005 1440 1461 15769636
  90. [96]Montano M.M. Jaiswal A.K. Katzenellenbogen B.S. Transcriptional regulation of the human quinone reductase gene by antiestrogen-liganded estrogen receptor-alpha and estrogen receptor-beta J. Biol. Chem. 273 1998 25443 25449 9738013
  91. [98]Graham D.G. Tiffany S.M. Bell W.R. Jr. Gutknecht W.F. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro Mol. Pharmacol. 14 1978 644 653 567274
  92. [99]Zafar K.S. Siegel D. Ross D. A potential role for cyclized quinones derived from dopamine, DOPA, and 3,4-dihydroxyphenylacetic acid in proteasomal inhibition Mol. Pharmacol. 70 2006 1079 1086 16790533
  93. [100]Herrera A. Munoz P. Steinbusch H.W.M. Segura-Aguilar J. Are dopamine oxidation metabolites involved in the loss of dopaminergic neurone in the nigrstriatal system in Parkinson's Disease? ACS Chem. Neurosci. 8 2017 702 711 28233992
  94. [101]Segura-Aguilar J. Lind C. On the mechanism of the Mn-induced neurotoxicity of dopamine:Prevention of quinone derived oxygen toxicity by DT-diaphorase and superoxide dismutase Chem. Biol. Interact. 72 1989 309 324 2557982
  95. [102]Cassagnes L.E. Perio P. Ferry G. Moulharat N. Antoine M. Gayon R. Boutin J.A. Nepveu F. Reybier K. In cellulo monitoring of quinone reductase activity and reactive oxygen species production during the redox cycling of 1,2 and 1,4 quinones Free Radic. Biol. Med. 89 2015 126 134 26386287
  96. [103]Segura-Aguilar J. On the role of aminochrome in mitochondrial dysfunction and endoplasmic reticulum stress in Parkinson's disease Front. Neurosci. 13 2019 271 30983959 PMC6449441
  97. [104]Munoz P. Cardenas S. Huenchuguala S. Briceno A. Couve E. Paris I. Segura-Aguilar J. DT-diaphorase prevents aminochrome-induced alpha-synuclein oligomer formation and neurotoxicity Toxicol. Sci. 145 2015 37 47 25634539 PMC4833033
  98. [105]Melendez C. Munoz P. Segura-Aguilar J. DT-diaphorase prevents aminochrome-induced lysosome dysfunction in SH-SY5Y cells Neurotox. Res. 35 2019 255 259 30203271
  99. [106]Paris I. Perez-Pastene C. Cardenas S. Iturriaga-Vasquez P. Munoz P. Couve E. Caviedes P. Segura-Aguilar J. Aminochrome induces disruption of actin, alpha-, and beta-tubulin cytoskeleton networks in substantia-nigra-derived cell line Neurotox. Res. 18 2010 82 92 20087799
  100. [107]Briceno A. Munoz P. Brito P. Huenchuguala S. Segura-Aguilar J. Paris I.B. Aminochrome toxicity is mediated by inhibition of microtubules polymerization through the formation of adducts with tubulin Neurotox. Res. 29 2016 381 393 26345577
  101. [108]Munoz P.S. Segura-Aguilar J. DT-diaphorase protects against autophagy induced by aminochrome-dependent alpha-synuclein oligomers Neurotox. Res. 32 2017 362 367 28478529
  102. [109]Zafar K.S. Inayat-Hussain S.H. Siegel D. Bao A. Shieh B. Ross D. Overexpression of NQO1 protects human SK-N-MC neuroblastoma cells against dopamine-induced cell death Toxicol. Lett. 166 2006 261 267 16978807
  103. [110]Lozano J. Munoz P. Nore B.F. Ledoux S. Segura-Aguilar J. Stable expression of short interfering RNA for DT-diaphorase induces neurotoxicity Chem. Res. Toxicol. 23 2010 1492 1496 20849151
  104. [111]Herrera-Soto A. Diaz-Veliz G. Mora S. Munoz P. Henny P. Steinbusch H.W.M. Segura-Aguilar J. On the role of DT-diaphorase inhibition in aminochrome-induced neurotoxicity in Vivo. Neurotox Res 32 2017 134 140 28285345
  105. [112]Schultzberg M. Segura-Aguilar J. Lind C. Distribution of DT-diaphorase in the rat brain: biochemical and immunohistochemical studies Neuroscience 1988 763 776 2908055
  106. [113]van Muiswinkel F.L. de Vos R.A. Bol J.G. Andringa G. Jansen Steur E.N. Ross D. Siegel D. Drukarch B. Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra Neurobiol. Aging 25 2004 1253 1262 15312971
  107. [114]Traver R.D. Horikoshi T. Danenberg K.D. Stadlbauer T.H. Danenberg P.V. Ross D. Gibson N.W. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity Canc. Res. 52 1992 797 802 1737339
  108. [115]Traver R.D. Siegel D. Beall H.D. Phillips R.M. Gibson N.W. Franklin W.A. Ross D. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase) Br. J. Canc. 75 1997 69 75 PMC2222704 9000600
  109. [116]Tsvetkov P. Adamovich Y. Elliott E. Shaul Y. E3 ligase STUB1/CHIP regulates NAD(P)H:quinone oxidoreductase 1 (NQO1) accumulation in aged brain, a process impaired in certain Alzheimer disease patients J. Biol. Chem. 286 2011 8839 8845 21220432 PMC3058985
  110. [117]Siegel D. Anwar A. Winski S.L. Kepa J.K. Zolman K.L. Ross D. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1 Mol. Pharmacol. 59 2001 263 268 11160862
  111. [118]Siegel D. McGuinness S.M. Winski S.L. Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1 Pharmacogenetics 9 1999 113 121 10208650
  112. [119]Wu K.D.P. Chen S. Catalytic proerties of a naturally occurring mutant of human NAD(P)H:quinone oxidoreductase (DT-diaphorase) Pro-187 to Ser K, Y. Pathophysiology of Lipids Peroxides and Related Free Radicals 1998 Japan Scientific Societies Press Tokyo 135 148
  113. [120]Chen S. Wu K. Zhang D. Sherman M. Knox R. Yang C.S. Molecular characterization of binding of substrates and inhibitors to DT-diaphorase: combined approach involving site-directed mutagenesis, inhibitor-binding analysis, and computer modeling Mol. Pharmacol. 56 1999 272 278 10419545
  114. [121]Pey A.L. Megarity C.F. Timson D.J. FAD binding overcomes defects in activity and stability displayed by cancer-associated variants of human NQO1 Biochim. Biophys. Acta 1842 2014 2163 2173 25179580
  115. [122]Lienhart W.D. Gudipati V. Uhl M.K. Binter A. Pulido S.A. Saf R. Zangger K. Gruber K. Macheroux P. Collapse of the native structure caused by a single amino acid exchange in human NAD(P)H:quinone oxidoreductase(1.) FEBS J. 281 2014 4691 4704 25143260 PMC4612375
  116. [123]Medina-Carmona E. Palomino-Morales R.J. Fuchs J.E. Padin-Gonzalez E. Mesa-Torres N. Salido E. Timson D.J. Pey A.L. Conformational dynamics is key to understanding loss-of-function of NQO1 cancer-associated polymorphisms and its correction by pharmacological ligands Sci. Rep. 6 2016 20331 26838129 PMC4738246
  117. [124]Moscovitz O. Tsvetkov P. Hazan N. Michaelevski I. Keisar H. Ben-Nissan G. Shaul Y. Sharon M. A mutually inhibitory feedback loop between the 20S proteasome and its regulator, NQO1 Mol. Cell. 47 2012 76 86 22793692
  118. [125]Medina-Carmona E. Neira J.L. Salido E. Fuchs J.E. Palomino-Morales R. Timson D.J. Pey A.L. Site-to-site interdomain communication may mediate different loss-of-function mechanisms in a cancer-associated NQO1 polymorphism Sci. Rep. 7 2017 44532 28291250 PMC5349528
  119. [126]Pey A.L. Megarity C.F. Timson D.J. NAD(P)H quinone oxidoreductase (NQO1): an enzyme which needs just enough mobility, in just the right places Biosci. Rep. 39 2019 PMC6328894 30518535
  120. [127]Gaedigk A. Tyndale R.F. Jurima-Romet M. Sellers E.M. Grant D.M. Leeder J.S. NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations Pharmacogenetics 8 1998 305 313 9731717
  121. [128]Kiffmeyer W.R. Langer E. Davies S.M. Envall J. Robison L.L. Ross J.A. Genetic polymorphisms in the Hmong population: implications for cancer etiology and survival Cancer 100 2004 411 417 14716779
  122. [129]Kelsey K.T. Wiencke J.K. Christiani D.C. Zuo Z. Spitz M.R. Xu X. Lee B.K. Schwartz B.S. Traver R.D. Ross D. Ethnic variation in the prevalence of a common NAD(P)H:quinone oxidoreductase polymorphism and its implications for anticancer chemotherapy Br. J. Canc. 76 1997 852 854 PMC2228056 9328142
  123. [130]Chen J. Lin Y. Zhang R. Huang Z.J. Pan X.G. Contribution of NAD(P)H quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and risk of colorectal adenoma and colorectal cancer in Caucasians: a meta-analysis Arch. Med. Res. 43 2012 58 66 22306249
  124. [131]Ding R. Lin S. Chen D. Association of NQO1 rs1800566 polymorphism and the risk of colorectal cancer: a meta-analysis Int. J. Colorectal Dis. 27 2012 885 892 22215148
  125. [132]Yadav U. Kumar P. Rai V. NQO1 gene C609T polymorphism (dbSNP: rs1800566) and digestive tract cancer risk: a meta-analysis." Nutr. Canc. 70 2018 557 568 29652514
  126. [133]Guo Z.J. Feng C.L. The NQO1 rs1800566 polymorphism and risk of bladder cancer: evidence from 6,169 subjects Asian Pac. J. Cancer Prev. APJCP 13 2012 6343 6348 23464456
  127. [134]Lajin B. Alachkar A. The NQO1 polymorphism C609T (Pro187Ser) and cancer susceptibility: a comprehensive meta-analysis Br. J. Canc. 109 2013 1325 1337 PMC3778271 23860519
  128. [135]Hu W.G. Hu J.J. Cai W. Zheng M.H. Zang L. Wang Z.T. Zhu Z.G. The NAD(P)H: quinine oxidoreductase 1 (NQO1) gene 609 C>T polymorphism is associated with gastric cancer risk: evidence from a case-control study and a meta-analysis Asian Pac. J. Cancer Prev. APJCP 15 2014 2363 2367 24716985
  129. [137]Sekiguchi M. Seki M. Kawai T. Yoshida K. Yoshida M. Isobe T. Hoshino N. Shirai R. Tanaka M. Souzaki R. Watanabe K. Arakawa Y. Nannya Y. Suzuki H. Fujii Y. Kataoka K. Shiraishi Y. Chiba K. Tanaka H. Shimamura T. Sato Y. Sato-Otsubo A. Kimura S. Kubota Y. Hiwatari M. Koh K. Hayashi Y. Kanamori Y. Kasahara M. Kohashi K. Kato M. Yoshioka T. Matsumoto K. Oka A. Taguchi T. Sanada M. Tanaka Y. Miyano S. Hata K. Ogawa S. Takita J. Integrated multiomics analysis of hepatoblastoma unravels its heterogeneity and provides novel druggable targets NPJ Precis Oncol 4 2020 20 32656360 PMC7341754
  130. [138]Wu Y.L. Wang D. Peng X.E. Chen Y.L. Zheng D.L. Chen W.N. Lin X. Epigenetic silencing of NAD(P)H:quinone oxidoreductase 1 by hepatitis B virus X protein increases mitochondrial injury and cellular susceptibility to oxidative stress in hepatoma cells Free Radic. Biol. Med. 65 2013 632 644 23920313
  131. [139]Tada M. Yokosuka O. Fukai K. Chiba T. Imazeki F. Tokuhisa T. Saisho H. Hypermethylation of NAD(P)H: quinone oxidoreductase 1 (NQO1) gene in human hepatocellular carcinoma J. Hepatol. 42 2005 511 519 15763338
  132. [140]Huang N. Pei X. Lin W. Chiu J.F. Tao T. Li G. DNA methylation of a non-CpG island promoter represses NQO1 expression in rat arsenic-transformed lung epithelial cells Acta Biochim. Biophys. Sin. 50 2018 733 739 29889218
  133. [141]Robertson H. Dinkova-Kostova A.T. Hayes J.D. NRF2 and the ambiguous consequences of its activation during initiation and the subsequent stages of tumourigenesis Cancers 12 12 2020 PMC7761610 33276631
  134. [142]Baird L. Suzuki T. Takahashi Y. Hishinuma E. Saigusa D. Yamamoto M. Geldanamycin-derived HSP90 inhibitors are synthetic lethal with NRF2 Mol. Cell Biol. 40 22 2020 PMC7588872 32868290
  135. [143]Baird L. Yamamoto M. NRF2-dependent bioactivation of mitomycin C as a novel strategy to target KEAP1-NRF2 pathway activation in human cancer Mol. Cell Biol. 41 2 2020 PMC8093492 33139492
  136. [144]Huang X. Motea E.A. Moore Z.R. Yao J. Dong Y. Chakrabarti G. Kilgore J.A. Silvers M.A. Patidar P.L. Cholka A. Fattah F. Cha Y. Anderson G.G. Kusko R. Peyton M. Yan J. Xie X.J. Sarode V. Williams N.S. Minna J.D. Beg M. Gerber D.E. Bey E.A. Boothman D.A. Leveraging an NQO1 bioactivatable drug for tumor-selective use of poly(ADP-ribose) polymerase inhibitors Canc. Cell 30 2016 940 952 PMC5161231 27960087
  137. [145]Motea E.A. Huang X. Singh N. Kilgore J.A. Williams N.S. Xie X.J. Gerber D.E. Beg M.S. Bey E.A. Boothman D.A. NQO1-dependent, tumor-selective radiosensitization of non-small cell lung cancers Clin. Canc. Res. 25 2019 2601 2609 PMC6788754 30617135
  138. [146]Starcher C.L. Pay S.L. Singh N. Yeh I.J. Bhandare S.B. Su X. Huang X. Bey E.A. Motea E.A. Boothman D.A. Targeting base excision repair in cancer: NQO1-bioactivatable drugs improve tumor selectivity and reduce treatment toxicity through radiosensitization of human cancer Front Oncol 10 2020 1575 32974194 PMC7468503
  139. [147]Torrente L. Maan G. Oumkaltoum Rezig A. Quinn J. Jackson A. Grilli A. Casares L. Zhang Y. Kulesskiy E. Saarela J. Bicciato S. Edwards J. Dinkova-Kostova A.T. de la Vega L. High NRF2 levels correlate with poor prognosis in colorectal cancer patients and with sensitivity to the kinase inhibitor AT9283 Vitro. Biomolecules vol. 10 2020 PMC7600603 32992842
  140. [148]Park M.T. Oh E.T. Song M.J. Lee H. Choi E.K. Park H.J. NQO1 prevents radiation-induced aneuploidy by interacting with Aurora-A Carcinogenesis 34 2013 2470 2485 23803694
  141. [149]Ross D. Quinone reductases. Multitasking in the metabolic world Drug Metabol. Rev. 36 2004 639 654 15554240
  142. [150]Dinkova-Kostova A.T. Talalay P. NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector Arch. Biochem. Biophys. 501 1 2010 116 123 20361926 PMC2930038
  143. [151]Ross D. Siegel D. Functions of NQO1 in cellular protection and CoQ10 metabolism and its potential role as a redox sensitive molecular switch Front. Physiol. 8 2017 595 28883796 PMC5573868
  144. [153]Crane F.L. Sun I.L. Clark M.G. Grebing C. Low H. Transplasma-membrane redox systems in growth and development Biochim. Biophys. Acta 811 1985 233 264 3893544
  145. [154]Navas P. Villalba J.M. Lenaz G. Coenzyme Q-dependent functions of plasma membrane in the aging process Age (Dordr) 27 2005 139 146 23598620 PMC3458499
  146. [155]Hyun D.H. Hernandez J.O. Mattson M.P. de Cabo R. The plasma membrane redox system in aging Ageing Res. Rev. 5 2006 209 220 16697277
  147. [156]Takahashi T. Okamoto T. Kishi T. Characterization of NADPH-dependent ubiquinone reductase activity in rat liver cytosol: effect of various factors on ubiquinone-reducing activity and discrimination from other quinone reductases J. Biochem. 119 1996 256 263 8882715
  148. [157]Takahashi T. Shitashige M. Okamoto T. Kishi T. Goshima K. A novel ubiquinone reductase activity in rat cytosol FEBS Lett. 314 1992 331 334 1468565
  149. [158]Villalba J.M. Navarro F. Cordoba F. Serrano A. Arroyo A. Crane F.L. Navas P. Coenzyme Q reductase from liver plasma membrane: purification and role in trans-plasma-membrane electron transport Proc. Natl. Acad. Sci. U. S. A. 92 1995 4887 4891 7761418 PMC41812
  150. [159]Kagan V.E. Arroyo A. Tyurin V.A. Tyurina Y.Y. Villalba J.M. Navas P. Plasma membrane NADH-coenzyme Q0 reductase generates semiquinone radicals and recycles vitamin E homologue in a superoxide-dependent reaction FEBS Lett. 428 1998 43 46 9645471
  151. [160]Sharma M.K. Buettner G.R. Interaction of vitamin C and vitamin E during free radical stress in plasma: an ESR study Free Radic. Biol. Med. 14 1993 649 653 8392021
  152. [161]Lopez-Lluch G. Barroso M.P. Martin S.F. Fernandez-Ayala D.J. Gomez-Diaz C. Villalba J.M. Navas P. Role of plasma membrane coenzyme Q on the regulation of apoptosis Biofactors 9 1999 171 177 10416029
  153. [162]Massey V.P.G. Ballou Ballou Massey V.P.G. Oxidases and Related Redox Systems vol. I 1973 Baltimore University Press Baltimore 25 49
  154. [163]Muller F. Flavin radicals: chemistry and biochemistry Free Radic. Biol. Med. 3 1987 215 230 3311900
  155. [164]Siegel D. Gustafson D.L. Dehn D.L. Han J.Y. Boonchoong P. Berliner L.J. Ross D. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger Mol. Pharmacol. 65 2004 1238 1247 15102952
  156. [165]Zhu H. Jia Z. Mahaney J.E. Ross D. Misra H.P. Trush M.A. Li Y. The highly expressed and inducible endogenous NAD(P)H:quinone oxidoreductase 1 in cardiovascular cells acts as a potential superoxide scavenger Cardiovasc. Toxicol. 7 2007 202 211 17901563
  157. [166]Schelonka L.P. Siegel D. Wilson M.W. Meininger A. Ross D. Immunohistochemical localization of NQO1 in epithelial dysplasia and neoplasia and in donor eyes Invest. Ophthalmol. Vis. Sci. 41 2000 1617 1622 10845577
  158. [167]Siegel D. Ross D. Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues Free Radic. Biol. Med. 29 2000 246 253 11035253
  159. [168]Siegel D. Franklin W.A. Ross D. Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors Clin. Canc. Res. 4 1998 2065 2070 9748120
  160. [169]Smith D. Martin L.F. Wallin R. Human DT-diaphorase, a potential cancer protecting enzyme. Its purification from abdominal adipose tissue Canc. Lett. 42 1988 103 112 2460216
  161. [170]Palming J. Sjoholm K. Jernas M. Lystig T.C. Gummesson A. Romeo S. Lonn L. Lonn M. Carlsson B. Carlsson L.M. The expression of NAD(P)H:quinone oxidoreductase 1 is high in human adipose tissue, reduced by weight loss, and correlates with adiposity, insulin sensitivity, and markers of liver dysfunction J. Clin. Endocrinol. Metab. 92 2007 2346 2352 17405841
  162. [171]Schlager J.J. Powis G. Cytosolic NAD(P)H:(quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol Int. J. Canc. 45 1990 403 409 2307529
  163. [172]Lata S. Ali A. Sood V. Raja R. Banerjea A.C. HIV-1 Rev downregulates Tat expression and viral replication via modulation of NAD(P)H:quinine oxidoreductase 1 (NQO1) Nat. Commun. 6 2015 7244 26059226
  164. [173]Cheng S.T. Hu J.L. Ren J.H. Yu H.B. Zhong S. Wai Wong V.K. Kwan Law B.Y. Chen W.X. Xu H.M. Zhang Z.Z. Cai X.F. Hu Y. Zhang W.L. Long Q.X. Ren F. Zhou H.Z. Huang A.L. Chen J. Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx J. Hepatol. 74 2020 522 534 32987030
  165. [174]Vanni A. Fiore M. De Salvia R. Cundari E. Ricordy R. Ceccarelli R. Degrassi F. DNA damage and cytotoxicity induced by beta-lapachone: relation to poly(ADP-ribose) polymerase inhibition Mutat. Res. 401 1998 55 63 9639674
  166. [175]Pink J.J. Wuerzberger-Davis S. Tagliarino C. Planchon S.M. Yang X. Froelich C.J. Boothman D.A. Activation of a cysteine protease in MCF-7 and T47D breast cancer cells during beta-lapachone-mediated apoptosis Exp. Cell Res. 255 2000 144 155 10694431
  167. [176]Hwang J.H. Kim D.W. Jo E.J. Kim Y.K. Jo Y.S. Park J.H. Yoo S.K. Park M.K. Kwak T.H. Kho Y.L. Han J. Choi H.S. Lee S.H. Kim J.M. Lee I. Kyung T. Jang C. Chung J. Kweon G.R. Shong M. Pharmacological stimulation of NADH oxidation ameliorates obesity and related phenotypes in mice Diabetes 58 2009 965 974 19136651 PMC2661596
  168. [177]Siegel D. Dehn D.D. Bokatzian S.S. Quinn K. Backos D.S. Di Francesco A. Bernier M. Reisdorph N. de Cabo R. Ross D. Redox modulation of NQO1 PloS One 13 2018 e0190717 PMC5752044 29298345
  169. [178]Li L.S. Bey E.A. Dong Y. Meng J. Patra B. Yan J. Xie X.J. Brekken R.A. Barnett C.C. Bornmann W.G. Gao J. Boothman D.A. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of beta-lapachone for pancreatic cancer therapy Clin. Canc. Res. 17 2011 275 285 PMC4806682 21224367
  170. [179]Bey E.A. Reinicke K.E. Srougi M.C. Varnes M. Anderson V.E. Pink J.J. Li L.S. Patel M. Cao L. Moore Z. Rommel A. Boatman M. Lewis C. Euhus D.M. Bornmann W.G. Buchsbaum D.J. Spitz D.R. Gao J. Boothman D.A. Catalase abrogates beta-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers Mol. Canc. Therapeut. 12 2013 2110 2120 PMC3807805 23883585
  171. [180]Chakrabarti G. Silvers M.A. Ilcheva M. Liu Y. Moore Z.R. Luo X. Gao J. Anderson G. Liu L. Sarode V. Gerber D.E. Burma S. DeBerardinis R.J. Gerson S.L. Boothman D.A. Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, beta-lapachone Sci. Rep. 5 2015 17066 26602448 PMC4658501
  172. [181]Kim Y.H. Hwang J.H. Noh J.R. Gang G.T. Kim D.H. Son H.Y. Kwak T.H. Shong M. Lee I.K. Lee C.H. Activation of NAD(P)H:quinone oxidoreductase ameliorates spontaneous hypertension in an animal model via modulation of eNOS activity Cardiovasc. Res. 91 2011 519 527 21502369
  173. [182]Lee J.S. Park A.H. Lee S.H. Lee S.H. Kim J.H. Yang S.J. Yeom Y.I. Kwak T.H. Lee D. Lee S.J. Lee C.H. Kim J.M. Kim D. Beta-lapachone, a modulator of NAD metabolism, prevents health declines in aged mice PloS One 7 2012 e47122 23071729 PMC3469505
  174. [183]Kim H.J. Oh G.S. Shen A. Lee S.B. Choe S.K. Kwon K.B. Lee S. Seo K.S. Kwak T.H. Park R. So H.S. Augmentation of NAD(+) by NQO1 attenuates cisplatin-mediated hearing impairment Cell Death Dis. 5 2014 e1292 24922076 PMC4611728
  175. [184]Wignall S.M. Gray N.S. Chang Y.T. Juarez L. Jacob R. Burlingame A. Schultz P.G. Heald R. Identification of a novel protein regulating microtubule stability through a chemical approach Chem. Biol. 11 2004 135 146 15113003
  176. [185]Siegel D. Kepa J.K. Ross D. NAD(P)H:quinone oxidoreductase 1 (NQO1) localizes to the mitotic spindle in human cells PloS One 7 2012 e44861 22984577 PMC3439439
  177. [186]Siegel D. Bersie S. Harris P. Di Francesco A. Armstrong M. Reisdorph N. Bernier M. de Cabo R. Fritz K. Ross D. A redox-mediated conformational change in NQO1 controls binding to microtubules and alpha-tubulin acetylation Redox Biol 39 2021 101840 33360352 PMC7772575
  178. [187]North B.J. Verdin E. Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis PloS One 2 2007 e784 17726514 PMC1949146
  179. [188]Saxena A. Wong L.H. Kalitsis P. Earle E. Shaffer L.G. Choo K.H. Poly(ADP-ribose) polymerase 2 localizes to mammalian active centromeres and interacts with PARP-1, Cenpa, Cenpb and Bub 3, but not Cenpc Hum. Mol. Genet. 11 2002 2319 2329 12217960
  180. [189]Chang P. Coughlin M. Mitchison T.J. Tankyrase-1 polymerization of poly(ADP-ribose) is required for spindle structure and function Nat. Cell Biol. 7 2005 1133 1139 16244666
  181. [190]Kang H.J. Song H.Y. Ahmed M.A. Guo Y. Zhang M. Chen C. Cristofanilli M. Horiuchi D. Vassilopoulos A. NQO1 regulates mitotic progression and response to mitotic stress through modulating SIRT2 activity Free Radic. Biol. Med. 126 2018 358 371 30114477 PMC6170003
  182. [191]Lienhart W.D. Gudipati V. Macheroux P. The human flavoproteome Arch. Biochem. Biophys. 535 2013 150 162 23500531 PMC3684772
  183. [192]Becker D.F. Zhu W. Moxley M.A. Flavin redox switching of protein functions Antioxidants Redox Signal. 14 2011 1079 1091 PMC3113445 21028987
  184. [193]Zoltowski B.D. Schwerdtfeger C. Widom J. Loros J.J. Bilwes A.M. Dunlap J.C. Crane B.R. Conformational switching in the fungal light sensor Vivid Science 316 2007 1054 1057 17510367 PMC3682417
  185. [194]Zhou Y. Larson J.D. Bottoms C.A. Arturo E.C. Henzl M.T. Jenkins J.L. Nix J.C. Becker D.F. Tanner J.J. Structural basis of the transcriptional regulation of the proline utilization regulon by multifunctional PutA J. Mol. Biol. 381 2008 174 188 18586269 PMC2665032
  186. [195]Zhou Y. Zhu W. Bellur P.S. Rewinkel D. Becker D.F. Direct linking of metabolism and gene expression in the proline utilization A protein from Escherichia coli Amino Acids 35 2008 711 718 18324349 PMC2666929
  187. [196]Hill S. Austin S. Eydmann T. Jones T. Dixon R. Azotobacter vinelandii NIFL is a flavoprotein that modulates transcriptional activation of nitrogen-fixation genes via a redox-sensitive switch Proc. Natl. Acad. Sci. U. S. A. 93 1996 2143 2148 8700899 PMC39924
  188. [197]Neumann P. Weidner A. Pech A. Stubbs M.T. Tittmann K. Structural basis for membrane binding and catalytic activation of the peripheral membrane enzyme pyruvate oxidase from Escherichia coli Proc. Natl. Acad. Sci. U. S. A. 105 2008 17390 17395 18988747 PMC2582286
  189. [198]Russell P. Schrock H.L. Gennis R.B. Lipid activation and protease activation of pyruvate oxidase. Evidence suggesting a common site of interaction on the protein J. Biol. Chem. 252 1977 7883 7887 334771
  190. [199]Leung K.K. Shilton B.H. Chloroquine binding reveals flavin redox switch function of quinone reductase 2 J. Biol. Chem. 288 2013 11242 11251 23471972 PMC3630856
  191. [200]Janda E. Nepveu F. Calamini B. Ferry G. Boutin J.A. Molecular pharmacology of nrh: quinone oxidoreductase 2: a detoxifying enzyme acting as an undercover toxifying enzyme Mol. Pharmacol. 98 2020 620 633 32913139
  192. [201]Leung K.K. Shilton B.H. Binding of DNA-intercalating agents to oxidized and reduced quinone reductase 2 Biochemistry 54 2015 7438 7448 26636353
  193. [202]Chen S. Deng P.S. Bailey J.M. Swiderek K.M. A two-domain structure for the two subunits of NAD(P)H:quinone acceptor oxidoreductase Protein Sci. 3 1994 51 57 7511454 PMC2142469
  194. [203]Tedeschi G. Chen S. Massey V. DT-diaphorase. Redox potential, steady-state, and rapid reaction studies J. Biol. Chem. 270 1995 1198 1204 7836380
  195. [204]Hosoda S. Nakamura W. Hayashi K. Properties and reaction mechanism of DT diaphorase from rat liver J. Biol. Chem. 249 1974 6416 6423 4138437
  196. [205]Anoz-Carbonell E. Timson D.J. Pey A.L. Medina M. The catalytic cycle of the antioxidant and cancer-associated human NQO1 enzyme: hydride transfer, conformational dynamics and functional cooperativity Antioxidants 9 2020 PMC7554937 32825392
  197. [206]Hosoda S. Nakamura W. Hayashi K. Properties and reaction mechanism of DT diaphorase from rat liver J. Biol. Chem. 549 1974 6416 6423 4138437
  198. [207]Cavelier G. Amzel L.M. Mechanism of NAD(P)H:quinone reductase: ab initio studies of reduced flavin Proteins 43 2001 420 432 11340659
  199. [208]Faig M. Bianchet M.A. Talalay P. Chen S. Winski S. Ross D. Amzel L.M. Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: species comparison and structural changes with substrate binding and release Proc. Natl. Acad. Sci. U. S. A. 97 2000 3177 3182 10706635 PMC16212
  200. [209]Janke C. Montagnac G. Causes and consequences of microtubule acetylation Curr. Biol. 27 2017 R1287 R1292 29207274

200 of 260 shown

Cited by

Sorted by citations

Authors
Ross, D., & Siegel, D.
ORCID
Siegel, David
Venue
Redox Biology
Publisher
Elsevier BV
Published
2021-05
Volume
41
Pages
101950
ISSN
2213-2317
DOI
10.1016/j.redox.2021.101950
PMC
PMC8027776
Cited by
482
References
7
Language
en
Licence
Funders
National Institutes of Health (R01-DK109964)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review